{"id":72458,"date":"2026-08-13T18:04:10","date_gmt":"2026-08-13T10:04:10","guid":{"rendered":"https:\/\/flcube.com\/?p=72458"},"modified":"2026-08-13T18:04:11","modified_gmt":"2026-08-13T10:04:11","slug":"hybio-pharmaceutical-grants-wansheng-pharmaceutical-exclusive-china-license-for-semaglutides-glycemic-control-indication-in-up-to-rmb-182-5-million-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72458","title":{"rendered":"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#8217;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shenzhen Hybio Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/300199:SHE\">SHE: 300199<\/a>) announced that it has signed a <strong>collaboration agreement<\/strong> with <strong>Zhejiang Wansheng Pharmaceutical Co., Ltd.<\/strong> (&#8220;Wansheng Pharmaceutical&#8221;) for the <strong>glycemic control indication of Hybio&#8217;s semaglutide<\/strong> \u2014 a generic drug referencing Novo Nordisk&#8217;s <strong>Ozempic\/Wegovy<\/strong> with <strong>Phase 3 studies already completed<\/strong>. The two parties had previously entered into a collaboration in <strong>May 2024<\/strong> for the <strong>weight management indication<\/strong> of Hybio&#8217;s semaglutide, making this the second indication-specific agreement between the companies.<\/p>\n\n\n\n<h2 id=\"h-deal-terms\" class=\"wp-block-heading\">Deal Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Zhejiang Wansheng Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Semaglutide (generic referencing Ozempic\/Wegovy) \u2014 glycemic control indication<\/td><\/tr><tr><td><strong>License Scope<\/strong><\/td><td>Exclusive, non-transferable, sub-licensable license in Mainland China, Hong Kong, and Macau<\/td><\/tr><tr><td><strong>Licensee Role<\/strong><\/td><td>Marketing Authorization Holder (MAH); solely responsible for commercialization<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>RMB 12 million<\/strong><\/td><\/tr><tr><td><strong>Approval Milestone<\/strong><\/td><td><strong>RMB 18 million<\/strong> upon regulatory approval for glycemic control<\/td><\/tr><tr><td><strong>Supply Milestone<\/strong><\/td><td><strong>RMB 7.5 million<\/strong> upon first commercial batch delivery<\/td><\/tr><tr><td><strong>Sales Milestones<\/strong><\/td><td>Up to <strong>RMB 145 million<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Percentage of sales as stipulated in the contract (post-commercialization)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-status-hybio-s-semaglutide\" class=\"wp-block-heading\">Asset Status \u2013 Hybio&#8217;s Semaglutide<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Stage:<\/strong> <strong>Phase 3 studies completed<\/strong> \u2014 among the most advanced generic semaglutide programs in China<\/li>\n\n\n\n<li><strong>Reference Products:<\/strong> Novo Nordisk&#8217;s <strong>Ozempic<\/strong> (glycemic control) and <strong>Wegovy<\/strong> (weight management)<\/li>\n\n\n\n<li><strong>Existing Partnership:<\/strong> Collaboration for the <strong>weight management indication<\/strong> already in place since <strong>May 2024<\/strong>; this new agreement completes the pairing across both blockbuster indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 Generic Race:<\/strong> Semaglutide generics represent one of China&#8217;s most fiercely contested pharmaceutical battlegrounds, with the molecule&#8217;s patent cliff approaching and both glycemic control and weight management demand expanding rapidly.<\/li>\n\n\n\n<li><strong>Indication-Split Licensing Model:<\/strong> By separating glycemic control and weight management into distinct collaborations, Hybio optimizes partner selection per commercial channel and indication-specific market dynamics.<\/li>\n\n\n\n<li><strong>Deal Economics:<\/strong> With upfront, regulatory, supply, and sales milestones totaling up to approximately <strong>RMB 182.5 million<\/strong> plus royalties, the structure preserves Hybio&#8217;s upside while shifting commercialization execution and costs to Wansheng Pharmaceutical.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Regulatory submission and approval timelines for the glycemic control indication were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the development and commercialization of Hybio&#8217;s semaglutide for glycemic control. Actual results may differ due to risks including regulatory outcomes, pricing and reimbursement dynamics, and competitive intensity in the GLP-1 market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u4e09\u751f\u8513\u8fea\u7b7e\u7f72\u53f8\u7f8e\u683c\u9c81\u80bd\u6ce8\u5c04\u6db2\uff08\u8840\u7cd6\u63a7\u5236\u9002\u5e94\u75c7\uff09\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u4e09\u751f\u8513\u8fea\u7b7e\u7f72\u53f8\u7f8e\u683c\u9c81\u80bd\u6ce8\u5c04\u6db2\uff08\u8840\u7cd6\u63a7\u5236\u9002\u5e94\u75c7\uff09\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-14b32ab3-b6d8-4574-af73-f969ce03ba0f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u4e09\u751f\u8513\u8fea\u7b7e\u7f72\u53f8\u7f8e\u683c\u9c81\u80bd\u6ce8\u5c04\u6db2\uff08\u8840\u7cd6\u63a7\u5236\u9002\u5e94\u75c7\uff09\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\">\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u4e09\u751f\u8513\u8fea\u7b7e\u7f72\u53f8\u7f8e\u683c\u9c81\u80bd\u6ce8\u5c04\u6db2\uff08\u8840\u7cd6\u63a7\u5236\u9002\u5e94\u75c7\uff09\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u4e09\u751f\u8513\u8fea\u7b7e\u7f72\u53f8\u7f8e\u683c\u9c81\u80bd\u6ce8\u5c04\u6db2\uff08\u8840\u7cd6\u63a7\u5236\u9002\u5e94\u75c7\uff09\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-14b32ab3-b6d8-4574-af73-f969ce03ba0f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4361,287,1106,4896],"class_list":["post-72458","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hot-targets","tag-hybio-pharmaceutical","tag-she-300199","tag-wansheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#039;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (&quot;Wansheng Pharmaceutical&quot;) for the glycemic control indication of Hybio&#039;s semaglutide \u2014 a generic drug referencing Novo Nordisk&#039;s Ozempic\/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio&#039;s semaglutide, making this the second indication-specific agreement between the companies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72458\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#039;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (&quot;Wansheng Pharmaceutical&quot;) for the glycemic control indication of Hybio&#039;s semaglutide \u2014 a generic drug referencing Novo Nordisk&#039;s Ozempic\/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio&#039;s semaglutide, making this the second indication-specific agreement between the companies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72458\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T10:04:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T10:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72458#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72458\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#8217;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal\",\"datePublished\":\"2026-08-13T10:04:10+00:00\",\"dateModified\":\"2026-08-13T10:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72458\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hot targets\",\"Hybio Pharmaceutical\",\"SHE: 300199\",\"Wansheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72458#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72458\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72458\",\"name\":\"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide's Glycemic Control Indication in Up-to-RMB 182.5 Million Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-13T10:04:10+00:00\",\"dateModified\":\"2026-08-13T10:04:11+00:00\",\"description\":\"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (\\\"Wansheng Pharmaceutical\\\") for the glycemic control indication of Hybio's semaglutide \u2014 a generic drug referencing Novo Nordisk's Ozempic\\\/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio's semaglutide, making this the second indication-specific agreement between the companies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72458#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72458\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72458#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#8217;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide's Glycemic Control Indication in Up-to-RMB 182.5 Million Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (\"Wansheng Pharmaceutical\") for the glycemic control indication of Hybio's semaglutide \u2014 a generic drug referencing Novo Nordisk's Ozempic\/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio's semaglutide, making this the second indication-specific agreement between the companies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72458","og_locale":"en_US","og_type":"article","og_title":"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide's Glycemic Control Indication in Up-to-RMB 182.5 Million Deal","og_description":"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (\"Wansheng Pharmaceutical\") for the glycemic control indication of Hybio's semaglutide \u2014 a generic drug referencing Novo Nordisk's Ozempic\/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio's semaglutide, making this the second indication-specific agreement between the companies.","og_url":"https:\/\/flcube.com\/?p=72458","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T10:04:10+00:00","article_modified_time":"2026-08-13T10:04:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72458#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72458"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#8217;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal","datePublished":"2026-08-13T10:04:10+00:00","dateModified":"2026-08-13T10:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72458"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hot targets","Hybio Pharmaceutical","SHE: 300199","Wansheng Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72458#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72458","url":"https:\/\/flcube.com\/?p=72458","name":"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide's Glycemic Control Indication in Up-to-RMB 182.5 Million Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-13T10:04:10+00:00","dateModified":"2026-08-13T10:04:11+00:00","description":"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that it has signed a collaboration agreement with Zhejiang Wansheng Pharmaceutical Co., Ltd. (\"Wansheng Pharmaceutical\") for the glycemic control indication of Hybio's semaglutide \u2014 a generic drug referencing Novo Nordisk's Ozempic\/Wegovy with Phase 3 studies already completed. The two parties had previously entered into a collaboration in May 2024 for the weight management indication of Hybio's semaglutide, making this the second indication-specific agreement between the companies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72458#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72458"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72458#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide&#8217;s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72458"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72458\/revisions"}],"predecessor-version":[{"id":72460,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72458\/revisions\/72460"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}